PFBT
BCRX icon

Parkside Financial Bank & Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91K Buy
201
+53
+36% +$412 ﹤0.01% 2133
2025
Q4 		$1.16K Sell
148
-53
-26% -$383 ﹤0.01% 2295
2025
Q3 		$1.53K Buy
201
+14
+7% +$117 ﹤0.01% 2118
2025
Q2 		$1.68K Buy
187
+117
+167% +$1.09K ﹤0.01% 2061
2025
Q1 		$525 Buy
+70
New +$565 ﹤0.01% 2351

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Parkside Financial Bank & Trust's BCRX Position: Q1 2026 in Review

Parkside Financial Bank & Trust increased its BioCryst Pharmaceuticals (BCRX) stake by 36% in Q1 2026, buying an estimated $412 and bringing the position to 201 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Parkside Financial Bank & Trust first reported a position in BCRX in Q1 2025 and has held it in 5 quarters since. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Parkside Financial Bank & Trust held 201 shares of BioCryst Pharmaceuticals worth $1.91K as of Q1 2026.
  • Parkside Financial Bank & Trust bought 53 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $412.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2133 holding.
  • Parkside Financial Bank & Trust first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.